FC analysis of tumor innate immune cell populations indicated that at day 6 after the first treatment, both VVL-TD-RFP and VVLΔTKΔN1L treatments significantly increased the proportion of DC, CD86+ DC, and major histocompatibility complex (MHC)-II+ DC compared with PBS (figure 3A). The gene discussed is CD86; the disease is neoplasm.